Intermittent claudication

Studies on clinical evaluation strategies and invasive treatment efficacy

Akademisk avhandling som för avläggande av medicine doktorsexamen vid Sahlgrenska Akademin vid Göteborgs Universitet kommer att offentligen försvaras i hörsal Arvid Carlsson, Academicum, Medicinaregatan 3, Göteborg, torsdagen den 5 juni 2014 kl. 9.00

av

Joakim Nordanstig
Leg. läkare

Fakultetsopponent:
Erik Wahlberg, adjungerad professor i kärlkirurgi vid Hälsouniversitetet, Linkköpings Universitet

Avhandlingen baseras på följande delarbeten:


Intermittent claudication
Studies on clinical evaluation strategies and invasive treatment efficacy
Joakim Nordanstig
Department of Molecular and Clinical Medicine
Institute of Medicine
The Sahlgrenska Academy

ABSTRACT

Peripheral arterial disease is a common health problem that globally affects over 200 million individuals, and intermittent claudication (IC) is the most common symptomatic presentation. The leg symptoms in IC are provoked by walking exercise and can be alleviated by medical intervention, exercise training and invasive vascular interventions (revascularization). The quality of evidence for invasive treatment is low and the efficacy, in terms of patient-oriented endpoints (e.g. health-related quality of life, HRQoL, and walking capacity), remains to be established. Appropriate validated instruments for the evaluation of HRQoL in IC are scarce, and accurate clinical evaluation of walking capacity remains challenging. The main aim of this thesis was to investigate the efficacy of a primary invasive versus a primary non-invasive treatment strategy in IC patients receiving best medical treatment and a structured non-supervised exercise program. Secondary aims were to validate and develop HRQoL instruments in IC, and to study the ability of different walk tests to mirror free-living walking capacity and HRQoL.

The efficacy of revascularization was investigated in two randomized controlled trials (study I and V). A disease-specific HRQoL instrument (VascuQoL) was validated within a Swedish context in a prospective cohort study (study II), and the feasibility of a short version was explored (study III). The correlations of three clinically used walking capacity estimates with GPS-assessed “real-life” outdoors walking capacity and HRQoL were investigated in another cohort study.

We found that a primary invasive treatment strategy improved HRQoL (study I) and HRQoL and claudication distance (study V) during follow-up. Validity of the Swedish version of the VascuQoL was established (study II), and a promising short version (VascuQoL-6) could be developed (study III). The six-minutes walk test was shown to correlate closely to “real-life” outdoor walking capacity and HRQoL.

In conclusion, we established that a primary strategy of revascularization, when added to best medical treatment and structured non-supervised exercise training, improves quality of life and important aspects of walking capacity in patients with intermittent claudication. The Swedish version of the VascuQoL is valid in the assessment of HRQoL in IC and the VascuQoL-6 holds promise for practical use in routine clinical care. The six-minutes walk test could be recommended in the clinical evaluation strategy of IC patients.

Keywords: peripheral arterial disease, intermittent claudication, endovascular procedures, quality of life, exercise, revascularization, health-related quality of life, disease-specific instruments, walking capacity, walk test